Hilleman CEO On Cost Gains From A Simpler Cholera Vaccine
Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.
You may also be interested in...
Hilleman Laboratories' CEO believes the Indian venture’s oral cholera vaccine could become the best in its class, telling Scrip cost-effectiveness is critical amid growing budgetary strains and outlining plans for a convenient tablet form.
France's Valneva has cemented its position in the traveler's vaccine market, acquiring Crucell's cholera and traveler's diarrhea vaccine Dukoral for €45m.
Hilleman Laboratories, the joint venture between Merck & Co and Wellcome Trust, and Gotovax AB, a University of Gothenburg spin-off biopharma firm, have outlined plans to develop a cut-price oral cholera vaccine that could potentially address some of the key limitations of existing products for the deadly disease.